# Combination Treatment for Augmenting Language in Children With ASD

> **NCT02574741** · PHASE2 · COMPLETED · sponsor: **University of California, Los Angeles** · enrollment: 58 (actual)

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **BEHAVIORAL:** Behavioral Therapy
- **DRUG:** Aripiprazole
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02574741
- **Lead sponsor:** University of California, Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2020-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02574741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02574741, "Combination Treatment for Augmenting Language in Children With ASD". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02574741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*